← Browse by Condition
Medical Condition
previously treated myelodysplastic syndrome
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT01624805 Phase 2
Recruiting
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Enrollment
140 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT02115295 Phase 2
Recruiting
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Enrollment
508 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center